Evidence map›Paper›PMID 42015200›Full record

ArticleBMC biotechnology2026

Sustained-release enteric formulations of Lactiplantibacillus plantarum based on granulation technology: preparation and therapeutic evaluation in acute colitis.

Xiwei Zhang, Jianfeng Wan, Xile Wang, Xiaocan Zhang, Miaomiao Jiang, Shuang Liang, Hongqing Zhang, Guangzhou Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiwei ZhangCollege of Biological Engineering, Henan University of Technology, No. 100 Lianhua Street, Zhengzhou, 450052, China.
Jianfeng WanCollege of Biological Engineering, Henan University of Technology, No. 100 Lianhua Street, Zhengzhou, 450052, China.
Xile WangCollege of Biological Engineering, Henan University of Technology, No. 100 Lianhua Street, Zhengzhou, 450052, China.
Xiaocan ZhangCollege of Biological Engineering, Henan University of Technology, No. 100 Lianhua Street, Zhengzhou, 450052, China.
Miaomiao JiangCollege of Biological Engineering, Henan University of Technology, No. 100 Lianhua Street, Zhengzhou, 450052, China.
Shuang LiangCollege of Biological Engineering, Henan University of Technology, No. 100 Lianhua Street, Zhengzhou, 450052, China.
Hongqing ZhangZhengzhou Qinghuayuan Bioengineering Co. Ltd, No. 5 Hehuan Street, Zhengzhou, 450052, China.
Guangzhou ZhouCollege of Biological Engineering, Henan University of Technology, No. 100 Lianhua Street, Zhengzhou, 450052, China. gzzhou@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical effectiveness of orally administered probiotics is often limited by poor survival during gastrointestinal transit and insufficient delivery to the intestinal site of action. Lactiplantibacillus plantarum, a probiotic with anti-inflammatory potential, is highly sensitive to gastric acid and bile salts, diminishing its therapeutic efficacy for intestinal diseases. The aim of this study was to develop an enteric sustained-release granule formulation of Lactobacillus plantarum to enhance probiotic stability, promote targeted intestinal delivery, and evaluate its therapeutic efficacy in the treatment of colitis.

methodsSustained-release enteric pellets containing Lactiplantibacillus plantarum were prepared using a low-temperature wet granulation and extrusion process, followed by coating with pH-responsive polymers (HPMCP or Eudragit L100). In vitro release behavior was evaluated in simulated gastric and intestinal fluids. Therapeutic efficacy was assessed in a dextran sulfate sodium (DSS)-induced acute colitis mouse model using histopathology, macrophage polarization, and gut microbiota analysis.

resultsThe sustained-release granules exhibited a narrow and uniform particle size distribution, with diameters ranging from 40 to 80 mesh (180–425 μm). More than 85% of the granules were distributed within the 40–60 mesh fraction (250–425 μm). The micropellets exhibited adequate mechanical strength for handling and processing. The enteric-coated micropellets showed pronounced acid resistance, retaining over 70% bacterial viability after 2 h in simulated gastric fluid, compared with <30% for free bacterial powder. In simulated intestinal fluid, the micropellets achieved sustained bacterial release for over 2 h. In DSS-induced colitis mice, treatment with the granule formulations resulted in a more pronounced trend toward histological recovery. Moreover, the sustained-release granules promoted M2 macrophage polarization and partially restored gut microbial diversity, as evidenced by normalization of the Firmicutes-to-Bacteroidetes ratio.

conclusionsThe sustained-release enteric pellet system effectively protects Lactiplantibacillus plantarum during gastrointestinal transit and achieves targeted intestinal release. Integrating mechanical shielding with pH-triggered dissolution significantly enhances probiotic gastrointestinal survival and therapeutic efficacy. This delivery platform represents a safe, scalable, and broadly applicable strategy for treating intestinal inflammatory diseases. Furthermore, the approach provides a versatile framework for delivering other probiotic strains or combinations.

Indexed as

ColitisLactiplantibacillus plantarumProbioticsAnimalsDelayed-Action PreparationsDextran SulfateHydrogen-Ion ConcentrationMiceParticle SizePolymethacrylic AcidsDelayed-Action PreparationsDextran Sulfatemethylmethacrylate-methacrylic acid copolymerPolymethacrylic AcidsAcute colitisEnteric sustained-release pelletsEudragit L100HPMCPLactiplantibacillus plantarum

Identifiers

PMID42015200
PMCPMC13231606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.